Addiction

Awakn Life Sciences Announces Listing on the Canadian Securities Exchange

Toronto, Ontario--(Newsfile Corp. - February 12, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a…

11 months ago

Ibogaine By David Dardashti Makes Statement on Public Concerns Regarding Fentanyl Distribution

David Dardashti Helping Our Clients is Our Top Priority. Miami, Feb. 10, 2024 (GLOBE NEWSWIRE) -- In light of the…

11 months ago

Southeast Primary Care Partners Choose Mental Health Technologies for Behavioral Health Screening

AURORA, IL / ACCESSWIRE / February 6, 2024 / With the mission of enabling primary care providers to provide comprehensive…

11 months ago

Safe Supply Streaming Endorses B.C. Government’s Expansion of Safer-Supply Program amid Drug Crisis

Vancouver, British Columbia--(Newsfile Corp. - February 5, 2024) - Safe Supply Streaming Co. Ltd. (CSE: SPLY) (FSE: QM4) (OTCQB: SSPLF) ("Safe…

11 months ago

Awakn Life Sciences Announces Conditional Approval of CSE Listing

Toronto, Ontario--(Newsfile Corp. - February 5, 2024) - Awakn Life Sciences Corp. (CBOE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn"), a…

11 months ago

MEDITECH to Showcase What Makes Expanse the Intelligent EHR at HIMSS 2024

Visit booth #2580 to learn how Expanse’s open platform elevates the patient journey.CANTON, Mass.--(BUSINESS WIRE)--Join MEDITECH at HIMSS 2024, March…

11 months ago

Retreat Behavioral Health Offers Free Virtual Workshops to Families and Friends of Patients

Substance Abuse and Mental Health Recovery Innovator Retreat Behavioral Health Extends Healing and Support Resources to Patient Family MembersPALM SPRINGS,…

11 months ago

Specialty-Driven Platforms Outperform Broad-Spectrum EHRs in Top 2024 Physician Satisfaction Ratings, 14th Annual Black Book Ambulatory Practice Surveys

Ninety-three percent of independent medical providers agree that specialist-specific EHRs position them best for value-based reimbursement, practice management and patient…

11 months ago

AlzeCure Selects Drug Candidate and Enters Next Phase of Development with TrkA-NAM ACD137 against Severe Pain

STOCKHOLM, SWEDEN / ACCESSWIRE / January 29, 2024 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) AlzeCure Pharma AB (publ) (FN STO: ALZCUR, a…

11 months ago